Skip to main content

Pharma/Regulatory

PEXIVAS: Diffuse Alveolar Hemorrhage in ANCA-Associated Vasculitis Patients

A secondary analysis of the PEXIVAS study showed antineutrophil cytoplasmic antibody–associated vasculitis (AAV) patients complicated by diffuse alveolar hemorrhage (DAH) may have improved with plasma exchange and glucocorticoids, the results did not achieve significance. 

Diffuse

Read Article
Drug Safety Update, from UK MHRA, shows impt interaction between tramadol and warfarin. Tramadol may increase the INR with risk of major bruising and bleeding when warfarin and tramadol are taken concomitantly. https://t.co/mgmeMJzdLa

Dr. John Cush @RheumNow( View Tweet )

Digital Self Screening for Arthritis Diagnosis

There are numerous impediments to diagnosis or referral; and a new study evaluates patient use of a mobile artificial intelligence (AI)–based symptom checker for diagnoses, but demonstrated only modest accuracy when applied to a cohort of patients with joint symptoms.

Read Article

Earlier RA Diagnosis Leads to Lower Costs of Care

A study from the Leiden Early Arthritis Clinic shows that is rheumatoid arthritis (RA) is diagnosed within 12 weeks after symptom onset, treatment costs were lower in both autoantibody-negative and autoantibody-positive RA. 

The rheumatologist

Read Article
ACR Comments on CMS Proposed 2025 Physician Payment Rule The American College of Rheumatology (ACR) shared the following initial reaction to the proposed CY 2025 Medicare Physician Fee Schedule (MPFS) and Quality Payment Program rule. https://t.co/l5aUWiCtQE https://t.co/7jQdouVRbm
Dr. John Cush @RheumNow( View Tweet )

Updated EULAR Recommendations on the Treatment of Systemic Sclerosis

Medscape

Medscape has published an overview to the 2024 updated recommendations for the treatment of systemic sclerosis (SSc) presented in Vienna at EULAR 2024 by Professor Francesco Del Galdo, MD, PhD on behalf of a 27 member task force.

The new recommendations (n=20)

Read Article

Pollution and Autoimmunity (7.12.2024)

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article

PNAS & Nature Insights into Lupus Pathogenesis

Two prominent medical journals this week published new insights into the pathogenesis of systemic lupus erythematosus (SLE), with both inidicating promient roles for T cells in what is a classically viewed as a humoral (B cell) disorder. 

Read Article

Progress in SLE with new mRNA CAR-T cell Trial

Cartesian Therapeutics, has announced their first-in-class mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T) therapy has been given to the first systematic lupus erythematosus (SLE). patient in a Phase 2 open-label clinical trial. 

The investigational drug,

Read Article

ICYMI: Can Mycophenolate be Stopped in Stable SLE?

In patients with clinically stable systemic lupus erythematosus (SLE) and lupus nephritis, the withdrawal of mycophenolate mofetil was not significantly inferior to mycophenolate maintenance, but MMF withdrawal had numerically more reactivations, while MMF maintenance had more infections.

Read Article

ICYMI: 2023 EULAR Psoriatic Arthritis Recommendations

EULAR has updated its treatment recommendations from the prior 2019 guidelines, since there have been several newly developed agents. The updated guidance includes 7 overarching principles and 11 recommendations regarding treatment strategy and pharmacological therapies.

Read Article

ICYMI: 9 Facts about Leflunomide

Medscape has published an informative review of leflunomide, drawn from Dr. Eric Ruderman’s recent lecture on the subject at the February RWCS meeting in Maui. Here are some highpoints from this Medscape article and lecture.

Read Article

ICYMI: Enthesitis, Synovitis, and Tenosynovitis in Psoriatic Arthritis

An ultrasound study suggests that enthesitis is associated with both synovitis and tenosynovitis in patients with Psoriatic arthritis (PsA).

Read Article

ICYMI: 2023 EULAR Non-pharmacological Management of Hip and Knee Osteoarthritis: 2023 update

EULAR has published the 2023 updated recommendations for the optimal non-pharmacological management of hip and knee osteoarthritis (OA).

Read Article

ICYMI: JAMA: SLE Review

Drs. Caroline Siegel and Lisa Sammaritano (from HSS in NYC) have published an impressive overview of systemic lupus erythematosus (SLE) in JAMA. This timely, well-written review covers the many complexities of this multi-organ disorder that affects nearly 3.4 million people worldwide.

Read Article

Future Big BiTEs (6.28.2024)

Dr. Jack Cush reviews the news, journal articles and regulatory announcements from the past week on RheumNow.com.

Read Article

Factors Affecting Hydroxychloroquine Adherence

A study from the University of British Columbia has evaluated the trajectories of hydroxychloroquine (HCQ) use in patients with incident RA and SLE between1997 and 2021, and identified factors associated with high adherence. 

From a total of 27,510 RA/SLE patients taking

Read Article

Difficult-to-Treat Psoriasis

This meta-analysis of psoriasis treatments shows that biologic therapies may be less effective in certain psoriasis (PSO) patients, particularly those who are older, smokers, with higher BMI an prior exposure to biologics.

Read Article

Protective Benefits of SGLT2 Inhibitors and Lupus Nephritis

A multicenter cohort study of systemic lupus erythematosus patients with type 2 diabetes has shown the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors associated with a significantly reduced risk of lupus nephritis, dialysis, kidney transplant, heart failure, and all-cause mortality

Read Article

No Risk of Interstitial Lung Disease with Methotrexate Use

JAMA reports a cohort study that investigated the association between methotrexate (MTX) use and Interstitial lung disease (ILD) in patients with dermatomyositis (DM).

Read Article

EULAR 2024 Rheumatology Roundup (6.21.2024)

Drs. Artie Kavanaugh and Jack Cush discuss highlights from the EULAR 2024 meeting in Vienna

Read Article

EULAR 2024 – Day 4 Report

The final day of EULAR 2024 was rich in posters, Late-breaking oral presentations and EULAR updates and recommendations.  Below is a synopsis of the half-day's action.

Read Article

Achieving drug-free remission in axSpA

EurekAlert!

A clinical trial in early axial spondyloarthritis (axSpA) demonstrated sustained inactive disease status in over 60% of patients. In axSpA patients with less than 1 year of disease symptoms, male sex, abstinence from smoking and lower BASDAI score at baseline were associated with higher

Read Article

Impact of regulatory warning on JAK inhibitors

The development of JAK inhibitors represents an advance for the treatment of inflammatory rheumatic diseases. However, the enthusiasm in using this target has waned since the publication of the ORAL surveillance clinical trial in 2022. Subsequently, both the FDA and EMA issued a warning on using

Read Article

The art of talking about risks with our patients

On the first day of EULAR 2024, I am debating Janet Pope. To make it more challenging, it’s about JAK inhibitor safety, and I have been allocated to argue against the regulatory safety warning and

Read Article